Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
PE-22-28: Bloodwork Guide
Recommended lab tests and biomarkers to monitor before, during, and after PE-22-28 therapy. Testing schedules are based on clinical protocols and published monitoring guidelines.
Back to PE-22-28 overviewDuring Treatment (1 test)
| Biomarker | Expected Effect | Retest |
|---|---|---|
| BDNF | ↑ increases | Every 8 weeks |